Becton, Dickinson and Company $BDX Shares Newly Acquired by International Assets Investment Management LLC

Key Points

• International Assets Investment Management acquired 90,000 Becton, Dickinson and Company shares in the third quarter, valued at approximately $16.1 million. Institutional investors and hedge funds collectively own 86.97% of BDX.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $185.07, though ratings range from “Strong Buy” to “Underweight.”
• BDX shares opened at $197.48, near their 12-month high of $200.47. The company recently exceeded quarterly earnings and revenue expectations, reporting $3.23 in EPS and $4.98 billion in revenue.

International Assets Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 90,000 shares of the medical instruments supplier's stock, valued at approximately $16,110,000.

A number of other large investors also recently added to or reduced their stakes in BDX. TD Waterhouse Canada Inc. grew its stake in Becton, Dickinson and Company by 17.1% in the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier's stock valued at $14,715,000 after acquiring an additional 14,077 shares during the period. Northside Capital Management LLC raised its position in shares of Becton, Dickinson and Company by 18.3% during the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier's stock worth $9,280,000 after purchasing an additional 9,494 shares during the period. NewEdge Advisors LLC raised its position in shares of Becton, Dickinson and Company by 35.0% during the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier's stock worth $6,923,000 after purchasing an additional 11,414 shares during the period. Beverly Hills Private Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $3,353,000. Finally, Wealthfront Advisers LLC bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $2,567,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BDX has been the subject of a number of research reports. Bank of America increased their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Monday, August 31st. Citigroup reaffirmed a "buy" rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. UBS Group began coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price target for the company. Zacks Research raised shares of Becton, Dickinson and Company from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, October 21st. Finally, Barclays assumed coverage on shares of Becton, Dickinson and Company in a report on Wednesday, October 7th. They set an "underweight" rating and a $165.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $185.07.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $197.48 on Friday. The company's fifty day simple moving average is $186.58 and its 200-day simple moving average is $170.26. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm has a market cap of $54.41 billion, a PE ratio of 59.48, a P/E/G ratio of 13.34 and a beta of 0.21. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $200.47.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the prior year, the company posted $3.68 earnings per share. The firm's revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of the company's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company's stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 6,907 shares of company stock valued at $1,269,128. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.